Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) will commence providing personalized CBD anti-tumor tests for patients suffering with cancer. The diagnostic tests are reliant on liquid biopsies of subjects suffering from any type of cancer. It uses CTC mechanism that collects cancer cells from subjects’ blood samples, and assesses their sensitivity to CBD compounds together with conventional chemotherapy drug.
The results allow physicians to make better informed decisions by offering personalized patient info as supporting proof to available medical therapies. Dr. Eyal Ballan, the Chief Scientist of Cannabics, reported that the objective is to embrace the natural medical properties of cannabis using the diversity of active composites to fight cancer in its appearance in each individual patient.
Through an exclusive deal with Cancer Hope Israel, which focuses on offering a comprehensive check of the success of chemotherapy and advanced biological drugs, Cannabics will offer its proprietary CBD based compounds to be evaluated in their anti-tumor properties. As per the latest update, commercialization will start in March, when 10 first subjects’ liquid biopsies will be assessed using this technology.
The firm intends to make this service accessible to cancer patients in the USA, Canada and Europe under local medicinal cannabis regulations, by the close of the year. Itamar Borochov, the CEO of Cannabics Pharmaceuticals, reported that they are the first firm in the world to provide cancer patients personalized CBD anti-tumor diagnostics. They are thrilled to be leaders in the nexus of cannabis and tailored cancer treatments.
Cancer Hope Israel is a Tailored Oncology Center that provides and represents advanced diagnostics for tailored cancer care. It collaborates with global leaders in medical and cancer diagnostics solutions in order to boost personalized oncology cure as a standard of treatment. As part of their objective they intend to bring together oncology experts with cutting-edge diagnostics, in attempt to provide the patients the best care.